Alternative Therapy and Abnormal Liver Function During Adjuvant Chemotherapy in Breast Cancer Patients by Ahn, Jin-Hee et al.
INTRODUCTION
The use of alternative therapy in cancer patients has become
increasingly popular, although this approach has not been
scientifically tested and has the potential to interact with con-
ventional treatment (1-6). To date, there have been no studies
prospectively investigating the use of alternative therapies in
breast cancer patients receiving adjuvant chemotherapy, or
determining the risk of abnormal liver function in concomi-
tantly treated patients. Also, there are few published reports
focusing on hepatotoxicity from chemotherapy with adriamy-
cin or the CMF (cytoxan+methotrexate+5-fluorouracil) regi-
men in adjuvant chemotherapy trial (7, 8). We previously
found that 34% of patients who had received adjuvant adri-
amycin followed by CMF chemotherapy for breast cancer
developed abnormal liver functions (9). Since many of our
patients were also taking various kinds of herbal medicines, a
majority of which are sold as ‘‘health food’’ without evidence
of proven efficacy or safety, we thought that the association
between these alternative therapies and abnormal liver function
warranted further study. We designed this study to determine
the frequency of hepatotoxicity during adjuvant chemother-
apy in breast cancer patients, and we compared results between
patients who had and had not taken alternative agents. 
MATERIALS AND METHODS
This study was conducted at an outpatient oncology clinic
on breast cancer patients who received adjuvant chemotherapy
from April through December 2002 with AC (adriamycin
60 mg/m2+cyclophosphamide 600 mg/m2, every 4 weeks)
after curative surgery and had normal liver functions prior to
chemotherapy. Each patient had a baseline history, a physical
examination, complete blood count (CBC) and liver function
test (LFT). The latter included assays for serum aspartate ami-
notransferase (AST), alanine aminotransferase (ALT), alkaline
phosphatase (ALP) and total bilirubin, as well as the hepatitis
B virus (HBV) markers, HBsAg and anti-HBs, anti-HCV
antibody, and a baseline liver ultrasonography within 2-4
weeks before chemotherapy. LFT was repeated before each
cycle of chemotherapy, one month after the last cycle and at
every 3 month follow-up visit after chemotherapy. Abnormal
LFT was defined as the elevation of aminotransferase (AST and/
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Alternative Therapy and Abnormal Liver Function During Adjuvant
Chemotherapy in Breast Cancer Patients
Although hepatotoxicity has been rarely reported during adjuvant chemotherapy in
breast cancer patients, we observed a high frequency in our patients who were also
taking alternative agents. We therefore sought to determine the association between
hepatotoxicity and alternative agents during adjuvant chemotherapy in breast cancer
patients. All breast cancer patients were treated with the same chemotherapeutic
regimen and had normal baseline liver function test (LFT). LFT was checked repeat-
edly during each cycle of chemotherapy. Patients showing LFT abnormalities were
asked about use of alternative agents, and, after the end of chemotherapy, a ques-
tionnaire was administered to each patient on their use of alternative agents. Of 178
patients, 65 (36.5%) admitted using alternative therapy, and significantly more patients
in this group developed LFT abnormalities (37/65, 56.9%) than those who denied
taking alternative therapy (25/113, 22.1%, p=0.001). Although LFT abnormalities
were mild to moderate and normalized in most patients after cessation of alternative
agents, it remained a serious problem in one patient. In conclusion, alternative therapy
may be one of the etiologies for abnormal LFT in breast cancer patients receiving
adjuvant chemotherapy. 
Key Words : Breast Neoplasms; Complementary Therapies; Drug Therapy; Hepatitis, Toxic
Received : 28 November 2003
Accepted : 11 February 2004398 J.-H. Ahn, S.-B. Kim, M.R. Yun, et al.
or ALT>40 IU/L) or bilirubin (>1.5 mg/dL) concentration.
Alternative agents were defined as any product, not approv-
ed for use in conventional medicine, including herbs, other
botanical agents or any biological preparations sold as ‘‘health
food.’’ Any patients found to have abnormal LFT during the
chemotherapy period were asked about the use of any alterna-
tive agent and requested to cease its use. If the liver function
did not return to normal after these agents were stopped, ultra-
sonography of the liver, and hepatitis panels for HBV and
HCV were repeated at the attending physician’s discretion.
Also, HBV DNA probe and HBeAg were assayed if the pati-
ent was an HBV carrier. After the end of chemotherapy, all
patients were interviewed by an oncology nurse specialist and
questionnaires were filled in for the history of use of any alter-
native agents. We used SPSS (version 11.0) statistical software
package for data entry and analysis. Chi-square test was used
for comparing the categorical variables between patients who
admitted taking alternative therapy and those who did not.
Statistical significance was defined as a p-value less than 0.05.
The protocol was reviewed and approved by the Clinical
Performance Improvement Project of our center. All patients
provided verbal informed consent before entering onto the
study. 
RESULTS
Patient characteristics 
During the study period, there were 203 patients with breast
cancer who had undergone curative surgery and received adju-
vant AC chemotherapy. Of these, 25 patients were excluded
because of abnormal LFT prior to chemotherapy. Thus, a total
of 178 breast cancer patients (median age, 46 yr; range, 29-
72), were included in this study. Six patients were HBsAg
carriers and one patient was positive in an anti-HCV antibody
test. Of the 150 patients for whom we had results of baseline
liver ultrasonography, 37 had underlying fatty liver disease.
Five patients received red blood cell transfusions during hos-
pitalization for breast surgery, but none had transfusions dur-
ing the chemotherapy period.
Alternative therapy 
At the first follow-up visit after the end of 4 cycles of chemo-
therapy, 65 (36.5%) patients admitted they had taken some
type of alternative agent(s) during chemotherapy period,
whereas 113 patients (63.5%) denied taking any alternative
agents. Duration of alternative therapy varied from 1 week
to 3 months. Steamed red Ginseng (Panax ginseng) was the
most common herbal therapy (35/65, 53.8%), and many
patients had taken several different agents (Table 1). Baseline
characteristics were similar between patients who admitted
using alternative therapies and those who did not (Table 2).
Abnormal liver function
We found that 62 of 178 patients (34.8%) developed abnor-
malities in LFT (Table 3). According to NCI common toxicity
criteria (Table 4), 43 patients (69.4%) had grade 1 toxicity,
16 (25.8%) had grade 2, 2 (3.2%) had grade 3, and 1 (1.6%)
had grade 4. Of the 65 patients who took alternative therapy,
37 (56.9%) developed an LFT abnormality, compared with
25/114 (22.1%) who denied taking alternative therapy (p=
0.001). Development of hepatotoxicity of grade 2 or higher
was significantly more common in the alternative therapy
group (13/65, 20.0%) than in the other group (6/113, 5.3%;
p=0.002). All patients who admitted using alternative agents
had started taking them one or two months before the LFT
Alternative therapy Examples
Herbs (70) Panax ginseng (ginseng steamed red 35), 
Daucus carota (carrot juice 15), other kinds of
ginseng (6), Ulmus davidiana (Slippery elm 6),
Angeliaca keiskei (2), Acer pictum (1), Yeast 
(1), Elentherococcus sessiliflorus (root bark of
various araliaceous shrubs 1), Euonymus
hamiltonianus (1), Morus alba (Mulberry leaves 
1), Mistletoe (1)
Diets (19)  Various uncooked grains and raw vegetables 
(12), ‘‘Pumpkin juice’’, ingredients unknown (3),
Vegetarian diet (2), ‘‘Pear juice’’, ingredients
unknown (1), ‘‘Grapefruit juice’’, ingredients
unknown (1)
Mushroom (13) Phelinus linteus (8), Ganoderma lucidum (5)
Others (7) Agaricus (3), Crucian juice (2), Royal jelly (1),
Shark cartilage (1)
Table 1. Alternative agents taken by our patients
*Numbers in the parenthesis are the numbers of patients.
With 
alternative therapy
Without 
alternative therapy
Total number of patients 65 (36.5%) 113 (63.5%)
Age (yr), median 44 (29-72) 46 (30-72)
BMI (kg/m
2)* 23.4 (18.9-28.6) 23.2 (17.5-35.7)
Hemoglobin, median 12.0 g/dL (9.0-14.1) 12.0 g/dL (9.0-14.4)
RBC transfusion  1 patient 4 patients 
AST* 20 IU/L(12-37) 20 IU/L (10-37)
ALT* 15 IU/L (6-40) 14 IU/L (3-40)
ALP* 50 IU/L (30-162) 52 IU/L (14-128)
Total bilirubin 0.7 mg/dL (0.2-1.3) 0.7 mg/dL (0.1-1.4)
HBV carrier  1 patient 5 patients
HCV Ab (+)  0 1 patient
Fatty liver disease 12/54 (22.2%) 25/97 (25.8%) 
Table 2. Patient characteristics according to the use of alternative
therapy
*Numbers are median value of BMI and liver function test.
BMI, body mass index; AST, aspartate aminotransferase; ALT, alanine
aminotransferase; ALP, alkaline phosphatase; HBV, hepatitis B virus; HCV
Ab, hepatitic C virus antibody.Alternative Therapy and Abnormal Liver Function 399
abnormality was detected. After discontinuing the agents,
however, the liver function abnormality was normalized within
a median 1.9 months (range, 1-8 months). In contrast, nor-
malization of liver function abnormalities took a median 2.9
months (range, 1-10 months) in the other group. 
The patient with grade 4 hepatotoxicity was an HBV carrier
who had used Panax ginseng and Ulmus davidiana (Slippery elm)
for 3 months from the beginning of adjuvant chemotherapy.
After the third cycle of chemotherapy, AST and ALT were
increased to 134 IU/L and 164 IU/L, respectively, and the
patient was asked to stop taking the alternative agents. After
the fourth cycle of chemotherapy, the patient presented with
further increases in AST and ALT to 748 IU/L and 732 IU/L,
respectively, and her bilirubin was 3.6 mg/dL. This resulted in
a delay in the administration of tamoxifen, and hospitalization
was required. No evidence for the replication of HBV was
observed, judging by the negative results of HBeAg and HBV
DNA probe, and liver ultrasonography showed a pattern of
non-specific chronic liver disease. It took more than 6 months
for the increased aminotransferases and bilirubin to return to
their normal ranges.
Significantly more patients who had underlying fatty liver
disease (18/37, 48.6%) developed abnormalities in LFT than
patients who did not (35/113, 30.7%; p=0.047). The frequen-
cy of underlying fatty liver disease was not different between
the patients who took alternative agents (22.2%) and those
who did not (25.8%). Of the 6 HBV carriers, 2 developed
abnormal LFT during chemotherapy, but there was no evi-
dence of viral replication.
DISCUSSION
Since data regarding hepatotoxicity during adjuvant chemo-
therapy in breast cancer patients is scarce, it is difficult to deter-
mine how often it occurs and what agents are involved. Mild
liver function abnormalities have been reported in 7% of breast
cancer patients after adjuvant CMF chemotherapy (7), whereas
the frequency of mild abnormal LFT within one year after the
cessation of CAF (cytoxan+adriamycin+5-fluorouracil) che-
motherapy was found to be 77%, suggesting that LFT abnor-
malities were manifestations of drug toxicity (8). Of these
patients, however, 33% (33/97) had abnormal liver functions
prior to the start of chemotherapy, an unusually high percent-
age. In contrast, only 25 of our 203 patients (12.3%) had
abnormal LFT before chemotherapy. 
In our study, 36.5% of breast cancer patients admitted using
alternative therapy during the adjuvant chemotherapy period.
The development of abnormal LFT was significantly more
frequent in these patients than in those who denied taking
alternative agents (56.9% vs. 22.1%, p=0.001). In most cases,
LFT abnormalities were mild to moderate, rarely led to inter-
ruption of chemotherapy, and normalized after the cessation
of alternative agents or spontaneously within several months,
even in patients who denied using alternative agents. These
results strongly indicate that alternative agents could cause
liver toxicity during adjuvant chemotherapy. 
In our study, two of six HBV carriers showed elevation of
aminotransferases during adjuvant chemotherapy, but there
was no evidence of HBV replication. The reactivation of HBV
infection in subjects receiving cytotoxic treatment has been
well documented in patients with hematologic malignancies
receiving steroid-containing high-dose chemotherapy (10-12).
Although the numbers of HBV carriers in our study is too
small to draw a firm conclusion, HBV carrier status alone
does not seem an additional risk factor for abnormal LFT.
Interests in alternative therapies have been increasing. In
previous population-based surveys, 48% and 72% of breast
cancer patients admitted using at least one type of alternative
therapy (4, 13). Among these alternative therapies were dietary
therapies, herbal remedies, spiritual healing, and psycholog-
ical methods, with the prevalence of each type dependent on
ethnicity (4). In our study, we considered only orally ingested
alternative therapies, perhaps explaining why the percentage
of our patients taking alternative treatment was lower than
those observed elsewhere. 
Some herbal and botanical agents possess complex biological
activities that could affect many aspects of carcinogenesis and
treatment (14, 15). Despite an extensive series of laboratory
studies, few clinical trials have tested the efficacy and safety
of these herbal and botanical agents. Heavy-metal contami-
nation is not uncommon in Asian herbal or botanical agents,
and these agents can act through a variety of mechanisms to
alter the pharmacokinetic profile of concomitantly adminis-
tered drugs (16, 17). Since several herbal remedies are associ-
ated with hepatotoxicity (18, 19), it was not surprising that
our patients who took alternative agents had a higher rate of
With alternative therapy
(No. of patients)
Abnormal liver
function test (LFT)
Without alternative 
therapy (No. of patients)
Incidence* 37/65 (56.9%) 25/113 (22.1%)
Grade 1/2/3/4 24/11/1/1 19/5/1/0 
Grade ≥2* 13/65 (20.0%) 6/113 (5.3%)
Time to normalization median 1.9 months  median 2.9 months 
of liver function (range 1-8 months) (range 1-10 months)
Table 3. Abnormal liver function according to the use of alternative
therapy 
*p-value< 0.05.
*AST, aspartate aminotransferase; ALT, alanine aminotransferase; 
� N,
upper normal limit.
Grade 1 2 3 4
AST, ALT* ≤2.5×N
� 2.6-5.0×N 5.1-20.0×N > 20.0×N
(IU/L) (≤100) (100-200) (200-800) (>800)
Total bilirubin <1.5×N 1.5-3.0×N >3.0×N
(mg/dL) (<1.8) (1.8-3.6) (>3.6)
Table 4. Hepatotoxicity according to NCI common toxicity criteriadeveloping abnormal liver function during the chemotherapy.
The alternative agents taken by our patients varied widely,
such that we could not sort out the agents responsible for hep-
atotoxicity. The determination of patients who ingested alter-
native agents was based totally on their own statements, and
it is our practice to discourage our patients from taking alter-
native agents. Thus, we cannot completely rule out the pos-
sibility that our patients under-reported usage of alternative
agents. In addition, we did not perform serial liver ultrasonog-
raphy on all patients who developed LFT abnormalities. There-
fore, we cannot determine precisely whether individual LFT
abnormalities are due to the use of alternative therapies, to
hepatotoxicity induced by chemotherapeutic agents, or to
aggravation of underlying fatty liver disease, either by chemo-
therapy or alternative agents. 
In conclusion, our results indicate that the use of alternative
agents can be one of the etiologies for the development of
abnormal LFT while on AC adjuvant chemotherapy in breast
cancer patients. Our findings suggest the need for more pros-
pective studies regarding the relative contribution to hepato-
toxicity by adjuvant chemotherapy and by alternative agents.
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